Disposition of 40000 shares by Okeeffe Charles B of Catalyst Pharmaceuticals at 4.01 subject to Rule 16b-3
| 84859BAB7 | 76.75 6.25 7.53% |
About 62% of 84859BAB7's investor base is looking to short. The analysis of the overall prospects from investing in SAVE 8 20 SEP 25 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 84859BAB7's historical and current headlines, can help investors time the market. In addition, many technical investors use SAVE 8 20 bond news signals to limit their universe of possible portfolio assets.
84859BAB7 |
Filed transaction by Catalyst Pharmaceuticals Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at news.google.com
 |
SAVE 8 20 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 84859BAB7 bond to make a market-neutral strategy. Peer analysis of 84859BAB7 could also be used in its relative valuation, which is a method of valuing 84859BAB7 by comparing valuation metrics with similar companies.
Peers
84859BAB7 Related Equities
| IH | Ihuman | 2.38 | ||||
| COE | 51Talk Online | 0.25 | ||||
| SNCY | Sun Country | 0.24 | ||||
| VRRM | Verra Mobility | 1.27 | ||||
| FLYX | FlyExclusive, | 2.45 | ||||
| SNDL | SNDL | 3.87 |
Other Information on Investing in 84859BAB7 Bond
84859BAB7 financial ratios help investors to determine whether 84859BAB7 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 84859BAB7 with respect to the benefits of owning 84859BAB7 security.